---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-25-000039"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T04:04:39.205618+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Nautilus Q1 net loss $16.6M, operating expenses down 13% YoY

## Summary
- Net loss $16.6M, improved from $18.7M in Q1 2024.
- Operating expenses $18.8M, down 13% from $21.6M prior year.
- Cash, equivalents, and investments $192.8M as of March 31, 2025.
- CEO reports progress on Tau proteoform assay toward commercial launch.

## SEC filing metadata
- accession: 0001808805-25-000039
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000039/0001808805-25-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000039/naut-20250429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-25-000039
- JSON: https://secwatch.observer/filing/0001808805-25-000039.json
- Plain text: https://secwatch.observer/filing/0001808805-25-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.